AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz, alleging infringement of AstraZeneca’s patent as a result of Teva’s and Sandoz’s filings of abbreviated new drug spplications (ANDAs). The ANDAs sought approval to market generic versions of Seroquel tablets in the US before Seroquel’s patent expires in 2011.
AstraZeneca’s motion for summary judgment of no inequitable conduct sought judgment on all of the remaining liability issues in the case. Teva and Sandoz had already conceded infringement and the validity of AstraZeneca’s patent.
David Brennan, CEO of AstraZeneca, said: “We are pleased with the court’s decision to uphold our valid intellectual property. Seroquel remains an important part of our company’s portfolio benefiting patients and physicians throughout the world.”